What is the projected market valuation for the Strongyloidiasis Treatment Market in 2035?

The projected market valuation for the Strongyloidiasis Treatment Market in 2035 is 1.707 USD Billion. Read More

What was the market valuation for the Strongyloidiasis Treatment Market in 2024?

The market valuation for the Strongyloidiasis Treatment Market in 2024 was 1.055 USD Billion. Read More

What is the expected CAGR for the Strongyloidiasis Treatment Market from 2025 to 2035?

The expected CAGR for the Strongyloidiasis Treatment Market during the forecast period 2025 - 2035 is 4.47%. Read More

Which drug type generated the highest revenue in the Strongyloidiasis Treatment Market?

Ivermectin generated the highest revenue in the Strongyloidiasis Treatment Market, with a valuation of 0.975 USD Billion. Read More

What are the key players in the Strongyloidiasis Treatment Market?

Key players in the Strongyloidiasis Treatment Market include GlaxoSmithKline, Merck & Co, Sanofi, and Pfizer. Read More

How does the revenue from homecare settings compare to that from hospitals in 2025?

In 2025, revenue from homecare settings is projected to be 0.502 USD Billion, compared to 0.6885 USD Billion from hospitals. Read More

What is the revenue forecast for the oral route of administration in 2035?

The revenue forecast for the oral route of administration in 2035 is expected to reach 0.999 USD Billion. Read More

Which treatment phase is anticipated to generate more revenue in 2035?

The acute phase is anticipated to generate more revenue in 2035, with a projected valuation of 0.999 USD Billion. Read More

What is the revenue range for Thiabendazole in the Strongyloidiasis Treatment Market?

The revenue range for Thiabendazole in the Strongyloidiasis Treatment Market is projected between 0.09 and 0.2 USD Billion. Read More

How does the revenue from clinics compare to that from hospitals in 2035?

In 2035, revenue from clinics is projected to be 0.5165 USD Billion, which is lower than the 0.6885 USD Billion expected from hospitals. Read More

Strongyloidiasis Treatment Market

ID: MRFR/LS/38730-HCR

100 Pages

Rahul Gotadki

Last Updated: April 06, 2026

Strongyloidiasis Treatment Market Research Report By Drug Type (Ivermectin, Albendazole, Thiabendazole, Mebendazole), By Route of Administration (Oral, Intravenous, Topical), By End User (Hospitals, Clinics, Homecare settings), By Treatment Phase (Acute Phase, Chronic Phase) and By Regional (North America, Europe, South America, Asia-Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Strongyloidiasis Treatment Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)4.47%

2024 Market Size$ 1.06 Billion

2025 Market Size$ 1.1 Billion

2035 Market Size$ 1.71 Billion

Key Players

GlaxoSmithKline

Merck & Co

Sanofi

Bristol-Myers Squibb

Pfizer

Novartis

Trends

Rising Awareness and Education
Innovative Therapeutic Developments
Integration of Digital Health Solutions

Opportunities

Emergence of Novel Therapeutics
Government Initiatives and Funding
Advancements in Diagnostic Techniques

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Drug Type (USD Billion)
  1. 4.1.1 Ivermectin
  2. 4.1.2 Albendazole
  3. 4.1.3 Thiabendazole
  4. 4.1.4 Mebendazole
2. 4.2 Healthcare, BY Route of Administration (USD Billion)
  1. 4.2.1 Oral
  2. 4.2.2 Intravenous
  3. 4.2.3 Topical
3. 4.3 Healthcare, BY End User (USD Billion)
  1. 4.3.1 Hospitals
  2. 4.3.2 Clinics
  3. 4.3.3 Homecare settings
4. 4.4 Healthcare, BY Treatment Phase (USD Billion)
  1. 4.4.1 Acute Phase
  2. 4.4.2 Chronic Phase
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 GlaxoSmithKline (GB)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Merck & Co (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Sanofi (FR)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Bristol-Myers Squibb (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Pfizer (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Novartis (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 AstraZeneca (GB)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 AbbVie (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Teva Pharmaceutical Industries (IL)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY DRUG TYPE
4. 6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
5. 6.5 US MARKET ANALYSIS BY END USER
6. 6.6 US MARKET ANALYSIS BY TREATMENT PHASE
7. 6.7 CANADA MARKET ANALYSIS BY DRUG TYPE
8. 6.8 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
9. 6.9 CANADA MARKET ANALYSIS BY END USER
10. 6.10 CANADA MARKET ANALYSIS BY TREATMENT PHASE
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY DRUG TYPE
13. 6.13 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
14. 6.14 GERMANY MARKET ANALYSIS BY END USER
15. 6.15 GERMANY MARKET ANALYSIS BY TREATMENT PHASE
16. 6.16 UK MARKET ANALYSIS BY DRUG TYPE
17. 6.17 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
18. 6.18 UK MARKET ANALYSIS BY END USER
19. 6.19 UK MARKET ANALYSIS BY TREATMENT PHASE
20. 6.20 FRANCE MARKET ANALYSIS BY DRUG TYPE
21. 6.21 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
22. 6.22 FRANCE MARKET ANALYSIS BY END USER
23. 6.23 FRANCE MARKET ANALYSIS BY TREATMENT PHASE
24. 6.24 RUSSIA MARKET ANALYSIS BY DRUG TYPE
25. 6.25 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
26. 6.26 RUSSIA MARKET ANALYSIS BY END USER
27. 6.27 RUSSIA MARKET ANALYSIS BY TREATMENT PHASE
28. 6.28 ITALY MARKET ANALYSIS BY DRUG TYPE
29. 6.29 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
30. 6.30 ITALY MARKET ANALYSIS BY END USER
31. 6.31 ITALY MARKET ANALYSIS BY TREATMENT PHASE
32. 6.32 SPAIN MARKET ANALYSIS BY DRUG TYPE
33. 6.33 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
34. 6.34 SPAIN MARKET ANALYSIS BY END USER
35. 6.35 SPAIN MARKET ANALYSIS BY TREATMENT PHASE
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY DRUG TYPE
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY END USER
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY TREATMENT PHASE
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY DRUG TYPE
42. 6.42 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
43. 6.43 CHINA MARKET ANALYSIS BY END USER
44. 6.44 CHINA MARKET ANALYSIS BY TREATMENT PHASE
45. 6.45 INDIA MARKET ANALYSIS BY DRUG TYPE
46. 6.46 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
47. 6.47 INDIA MARKET ANALYSIS BY END USER
48. 6.48 INDIA MARKET ANALYSIS BY TREATMENT PHASE
49. 6.49 JAPAN MARKET ANALYSIS BY DRUG TYPE
50. 6.50 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
51. 6.51 JAPAN MARKET ANALYSIS BY END USER
52. 6.52 JAPAN MARKET ANALYSIS BY TREATMENT PHASE
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY DRUG TYPE
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY END USER
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY TREATMENT PHASE
57. 6.57 MALAYSIA MARKET ANALYSIS BY DRUG TYPE
58. 6.58 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
59. 6.59 MALAYSIA MARKET ANALYSIS BY END USER
60. 6.60 MALAYSIA MARKET ANALYSIS BY TREATMENT PHASE
61. 6.61 THAILAND MARKET ANALYSIS BY DRUG TYPE
62. 6.62 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
63. 6.63 THAILAND MARKET ANALYSIS BY END USER
64. 6.64 THAILAND MARKET ANALYSIS BY TREATMENT PHASE
65. 6.65 INDONESIA MARKET ANALYSIS BY DRUG TYPE
66. 6.66 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
67. 6.67 INDONESIA MARKET ANALYSIS BY END USER
68. 6.68 INDONESIA MARKET ANALYSIS BY TREATMENT PHASE
69. 6.69 REST OF APAC MARKET ANALYSIS BY DRUG TYPE
70. 6.70 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
71. 6.71 REST OF APAC MARKET ANALYSIS BY END USER
72. 6.72 REST OF APAC MARKET ANALYSIS BY TREATMENT PHASE
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY DRUG TYPE
75. 6.75 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
76. 6.76 BRAZIL MARKET ANALYSIS BY END USER
77. 6.77 BRAZIL MARKET ANALYSIS BY TREATMENT PHASE
78. 6.78 MEXICO MARKET ANALYSIS BY DRUG TYPE
79. 6.79 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
80. 6.80 MEXICO MARKET ANALYSIS BY END USER
81. 6.81 MEXICO MARKET ANALYSIS BY TREATMENT PHASE
82. 6.82 ARGENTINA MARKET ANALYSIS BY DRUG TYPE
83. 6.83 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
84. 6.84 ARGENTINA MARKET ANALYSIS BY END USER
85. 6.85 ARGENTINA MARKET ANALYSIS BY TREATMENT PHASE
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG TYPE
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT PHASE
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY DRUG TYPE
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY END USER
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT PHASE
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY DRUG TYPE
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY END USER
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT PHASE
99. 6.99 REST OF MEA MARKET ANALYSIS BY DRUG TYPE
100. 6.100 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
101. 6.101 REST OF MEA MARKET ANALYSIS BY END USER
102. 6.102 REST OF MEA MARKET ANALYSIS BY TREATMENT PHASE
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY DRUG TYPE, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY DRUG TYPE, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY END USER, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY TREATMENT PHASE, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY TREATMENT PHASE, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.2.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.2.4 BY TREATMENT PHASE, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.3.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.3.4 BY TREATMENT PHASE, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.4.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.4.4 BY TREATMENT PHASE, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.5.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.5.4 BY TREATMENT PHASE, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.6.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.6.4 BY TREATMENT PHASE, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.7.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.7.4 BY TREATMENT PHASE, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.8.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.8.4 BY TREATMENT PHASE, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.9.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.9.4 BY TREATMENT PHASE, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.10.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.10.4 BY TREATMENT PHASE, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.11.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.11.4 BY TREATMENT PHASE, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.12.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.12.4 BY TREATMENT PHASE, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.13.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.13.4 BY TREATMENT PHASE, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.14.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.14.4 BY TREATMENT PHASE, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.15.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.15.4 BY TREATMENT PHASE, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.16.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.16.4 BY TREATMENT PHASE, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.17.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.17.4 BY TREATMENT PHASE, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.18.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.18.4 BY TREATMENT PHASE, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.19.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.19.4 BY TREATMENT PHASE, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.20.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.20.4 BY TREATMENT PHASE, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.21.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.21.4 BY TREATMENT PHASE, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.22.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.22.4 BY TREATMENT PHASE, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.23.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.23.4 BY TREATMENT PHASE, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.24.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.24.4 BY TREATMENT PHASE, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.25.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.25.4 BY TREATMENT PHASE, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.26.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.26.4 BY TREATMENT PHASE, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.27.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.27.4 BY TREATMENT PHASE, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.28.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.28.4 BY TREATMENT PHASE, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.29.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.29.4 BY TREATMENT PHASE, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.30.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.30.4 BY TREATMENT PHASE, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Strongyloidiasis Treatment Market Segmentation

Strongyloidiasis Treatment Market By Drug Type (USD Billion, 2025-2035)

Ivermectin
Albendazole
Thiabendazole
Mebendazole

Strongyloidiasis Treatment Market By Route of Administration (USD Billion, 2025-2035)

Oral
Intravenous
Topical

Strongyloidiasis Treatment Market By End User (USD Billion, 2025-2035)

Hospitals
Clinics
Homecare settings

Strongyloidiasis Treatment Market By Treatment Phase (USD Billion, 2025-2035)

Acute Phase
Chronic Phase

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”